RT Journal
A1 Shang C
T1 Β-blocker use for patients with or at risk for coronary artery disease
JF JAMA
JO JAMA
YR 2013
FD February 6
VO 309
IS 5
SP 438
OP 438
DO 10.1001/jama.2012.128869
UL http://dx.doi.org/10.1001/jama.2012.128869
AB 
To the Editor: It is unfortunate that the observational study on β-blocker use and clinical outcomes in stable outpatients did not distinguish different types of β-blockers.1 In a review of β-blockers for hypertension, three-quarters of participants in randomized controlled trials (RCTs) used atenolol.2 Atenolol has been shown repeatedly to be no better than placebo in improving clinical outcomes such as reduction of mortality and cardiovascular events in RCTs and meta-analyses.2- 3